TFPIβ is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes

Thomas J. Girard, Elodee Tuley, George J. Broze

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

Tissue factor pathway inhibitor (TFPI) produces factor Xa-dependent feedback inhibition of factor VIIa/tissue factor-induced coagulation. Messages for 2 isoforms of TFPI have been identified. TFPIα mRNA encodes a protein with an acidic N-terminus, 3 Kunitz-type protease inhibitor domains and a basic C-terminus that has been purified from plasma and culture media. TFPIβ mRNA encodes a form in which the Kunitz-3 and C-terminal domains of TFPIα are replaced with an alternative C-terminus that directs the attachment of a glycosylphosphatidylinositol (GPI) anchor, but whether TFPIβ protein is actually expressed is not clear. Moreover, previous studies have suggested that the predominant form of TFPI released from cells by phosphatidylinositol- specific phospholipase C (PIPLC) treatment is TFPIα, implying it is bound at cell surfaces to a separate GPI-anchored coreceptor. Our studies show that the form of TFPI released by PIPLC treatment of cultured endothelial cells and placental microsomes is actually TFPIβ based on (1) migration on SDS-PAGE before and after deglycosylation, (2) the lack of a Kunitz-3 domain, and (3) it contains a GPI anchor. Immunoassays demonstrate that, although endothelial cells secrete TFPIα, greater than 95% of the TFPI released by PIPLC treatment from the surface of endothelial cells and from placental microsomes is TFPIβ.

Original languageEnglish
Pages (from-to)1256-1262
Number of pages7
JournalBlood
Volume119
Issue number5
DOIs
StatePublished - Feb 2 2012

Fingerprint

Dive into the research topics of 'TFPIβ is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes'. Together they form a unique fingerprint.

Cite this